Arcutis Biotherapeutics ARQT 深 沪
交易中 11-05 10:19:17 美东时间
27.565
-6.485
-19.05%
华盛通- 最 高29.49
- 今 开29.00
- 成交量 132.99万股
- 最 低 26.771
- 昨 收 34.05
- 总市值 34.65亿
- 52周最高 34.80
- 市盈率 静 --
- 换手率 1.06%
- 52周最低 19.295
- 委 比 -25.65%
- 总股本 1.26亿
- 历史最高 40.88
- 量 比 8.02
- 振 幅 7.99%
- 历史最低 1.76
- 每 手 1
- 风险率 2.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arcutis Biotherapeutics Initiates Enrollment In Its INTEGUMENT-3 Trial To Evaluate ZORYVE To Treat Atopic Dermatitis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first participant has been enrolled in a Phase 3, double-blind, randomized, vehicle-controlled study, INTEGUMENT-3. ...
今天 21:02
Why AppLovin Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Shares of AppLovin Corporation (NASDAQ:APP) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and issued its fourth-quarter sales guidance above estimates. AppLovin reported third-quarter revenue of approximately $2.19 billion, topping...
今天 17:42
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
Arcutis Biotherapeutics has initiated the INTEGUMENT-3 Phase 3 study to evaluate ZORYVE® 0.3% cream for treating moderate to severe atopic dermatitis in individuals aged 6 and older. The study aims to expand the use of ZORYVE cream to more severe cases, building on its established efficacy for mild to moderate conditions. Approximately 415 participants will be randomized to receive ZORYVE cream 0.3% or vehicle cream for 4 weeks, with a potential ...
今天 13:00
财报速睇 | Arcutis Biotherapeutics 2026财年Q3营收1.44亿美元，同比增长45.1%；归母净利润0.09亿美元，同比增长18.8%
华盛资讯11月5日讯，Arcutis Biotherapeutics公布2026财年Q3业绩，公司Q3营收1.44亿美元，同比增长45.1%，归母净利润0.09亿美元，同比增长18.8%。
今天 11:32
财报速睇 | Arcutis Biotherapeutics 2026财年Q3营收1.44亿美元，同比增长45.1%；归母净利润0.09亿美元，同比增长18.8%
华盛资讯11月5日讯，Arcutis Biotherapeutics公布2026财年Q3业绩，公司Q3营收1.44亿美元，同比增长45.1%，归母净利润0.09亿美元，同比增长18.8%。
今天 09:32
Arcutis Biotherapeutics Announces $200M At-The-Market Common Stock Offering
ARCUTIS BIOTHERAPEUTICS, INC. $200,000,000 Common Stock We have entered into an amended and restated sales agreement, or the Sales Agreement, with TD Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of s...
今天 07:09
Arcutis Biotherapeutics收跌2.53%，成交额4791.59万美元
11月3日，Arcutis Biotherapeutics（ARQT）收跌2.53%，报31.26美元，成交额4791.59万美元，市值39.29亿美元。 行情...
11-03 06:10
Arcutis Biotherapeutics Adds Veteran Leader to Board
Arcutis Biotherapeutics ( ($ARQT) ) has shared an update. On October 23, 2026, ...
10-28 21:29
